Profile Rationale and Design of the PROSPECTIVE Trial : Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease

Department of Community Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan Rinku General Medical Center, Izumisano, Osaka, Japan Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan Department of Dental Anesthesiology, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan The National Center for Geriatrics and Gerontology, Obu, Aichi, Japan Department of Clinical Laboratory and Experimental Research Medicine, Toho University, Sakura Medical Center, Sakura, Chiba, Japan Foundation for Biomedical Research and Innovation, Kobe, Hyogo, Japan Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan Chiba University Graduate School of Medicine, Chiba, Japan Sumitomo Hospital, Osaka, Japan

[1]  T. Funahashi,et al.  Effects of probucol on xanthomata regression in familial hypercholesterolemia. , 1986, The American journal of cardiology.

[2]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Yamashita,et al.  Erratum: Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan [Journal of Atherosclerosis and Thrombosis 1506 292-303] , 2009 .

[4]  S. Yamashita,et al.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[5]  H. Daida,et al.  Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. , 2012, Atherosclerosis.

[6]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[7]  S. King,et al.  Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required , 2008, Circulation.

[8]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[9]  T. Miida,et al.  High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet. , 1998, Atherosclerosis.

[10]  S. Nattel,et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. , 1997, The New England journal of medicine.

[11]  R. N. Brogden,et al.  Probucol , 1989, Drugs.

[12]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[13]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[14]  S. Nattel,et al.  Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. , 1999, Circulation.

[15]  H. Daida,et al.  Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. , 1997, Journal of the American College of Cardiology.

[16]  Jianglin Fan,et al.  Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. , 2014, Journal of atherosclerosis and thrombosis.

[17]  S. Kihara,et al.  Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. , 2013, Journal of atherosclerosis and thrombosis.

[18]  S. Grundy,et al.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. , 2014, Journal of clinical lipidology.

[19]  Y. Abiko,et al.  Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice. , 1981, Atherosclerosis.

[20]  S. Nilsson,et al.  The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). , 1994, The American journal of cardiology.

[21]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[22]  T. Kita,et al.  The role of oxidized lipoproteins in the pathogenesis of atherosclerosis. , 1992, Clinical and experimental pharmacology & physiology. Supplement.

[23]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[24]  T. Nishide,et al.  Effect of 5-year administration of probucol on development of myocardial infarction in heterozygous familial hypercholesterolemia , 1993 .

[25]  H. Daida,et al.  Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). , 2000, The American journal of cardiology.

[26]  V. Lankin,et al.  Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients , 2007, Bulletin of Experimental Biology and Medicine.

[27]  S. Yamashita,et al.  Where are we with probucol: a new life for an old drug? , 2009, Atherosclerosis.

[28]  S. Humphries,et al.  A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. , 2003, Atherosclerosis.

[29]  M. Setsuda,et al.  Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. , 1993, Clinical therapeutics.

[30]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[31]  S. Kashiwagi,et al.  Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). , 2002, Journal of the American College of Cardiology.

[32]  Jonathan D. Smith.  Dysfunctional HDL as a diagnostic and therapeutic target. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[33]  S. Yamashita,et al.  High‐density lipoproteins from probucol‐treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low‐density lipoproteins , 1997, European journal of clinical investigation.

[34]  J. Wakasugi,et al.  Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. , 1988, The American journal of cardiology.

[35]  S. Grundy,et al.  Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers. , 1992, Atherosclerosis.

[36]  R. Vasan,et al.  Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. , 2013, Atherosclerosis.

[37]  A. Tall,et al.  Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  J. Werba,et al.  Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. , 1993, Metabolism: clinical and experimental.

[39]  J. Fruchart,et al.  Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles. , 2000, Atherosclerosis.

[40]  K. Shirai,et al.  A Comparative Study of the Therapeutic Effect of Probucol and Pravastatin on Xanthelasma , 1996, The Journal of dermatology.

[41]  A. Tall,et al.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.

[42]  A. Tall,et al.  Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[43]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[44]  Y. Abiko,et al.  Mode of Action of Probucol in Reducing Serum Cholesterol in Mice , 1983 .

[45]  J. Sj.  Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty , 1997 .

[46]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[47]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Yamashita,et al.  Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. , 2012, Journal of atherosclerosis and thrombosis.